HK1122729A1 - Gastroretentive formulations and manufacturing process thereof - Google Patents

Gastroretentive formulations and manufacturing process thereof

Info

Publication number
HK1122729A1
HK1122729A1 HK08113911.1A HK08113911A HK1122729A1 HK 1122729 A1 HK1122729 A1 HK 1122729A1 HK 08113911 A HK08113911 A HK 08113911A HK 1122729 A1 HK1122729 A1 HK 1122729A1
Authority
HK
Hong Kong
Prior art keywords
manufacturing process
formulations
gastroretentive formulations
gastroretentive
gelling agent
Prior art date
Application number
HK08113911.1A
Other languages
English (en)
Inventor
Mahendra Chaudhari
Omprakash D Chandwani
Rajashree S Yelegaonkar
Original Assignee
Ethypharm Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ethypharm Sa filed Critical Ethypharm Sa
Publication of HK1122729A1 publication Critical patent/HK1122729A1/xx

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38Cellulose; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0053Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0065Forms with gastric retention, e.g. floating on gastric juice, adhering to gastric mucosa, expanding to prevent passage through the pylorus
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/12Antihypertensives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605Excipients; Inactive ingredients
    • A61K9/1629Organic macromolecular compounds
    • A61K9/1652Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/205Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/205Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/28Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806Coating materials
    • A61K9/282Organic compounds, e.g. fats
    • A61K9/2826Sugars or sugar alcohols, e.g. sucrose; Derivatives thereof

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Inorganic Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Communicable Diseases (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Cosmetics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medical Preparation Storing Or Oral Administration Devices (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
HK08113911.1A 2005-07-19 2008-12-23 Gastroretentive formulations and manufacturing process thereof HK1122729A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP05291542A EP1745775B1 (en) 2005-07-19 2005-07-19 Gastroretentive formulations and manufacturing process thereof.
PCT/IB2006/002636 WO2007010400A2 (en) 2005-07-19 2006-07-19 Gastroretentive formulations and manufacturing process thereof

Publications (1)

Publication Number Publication Date
HK1122729A1 true HK1122729A1 (en) 2009-05-29

Family

ID=35517256

Family Applications (1)

Application Number Title Priority Date Filing Date
HK08113911.1A HK1122729A1 (en) 2005-07-19 2008-12-23 Gastroretentive formulations and manufacturing process thereof

Country Status (13)

Country Link
US (1) US9629800B2 (xx)
EP (2) EP1745775B1 (xx)
JP (1) JP5199084B2 (xx)
KR (1) KR101367814B1 (xx)
CN (1) CN101237858B (xx)
AT (1) ATE396710T1 (xx)
AU (1) AU2006271314B2 (xx)
BR (1) BRPI0612901B8 (xx)
CA (1) CA2616081C (xx)
DE (1) DE602005007205D1 (xx)
HK (1) HK1122729A1 (xx)
RU (1) RU2376983C2 (xx)
WO (1) WO2007010400A2 (xx)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20080076382A (ko) * 2007-02-15 2008-08-20 (주)아모레퍼시픽 실로스타졸의 제어방출 제제 및 그 제조방법
EP2346351B1 (en) 2008-09-22 2019-07-03 Rubicon Research Private Limited Compositions exhibiting delayed transit through the gastrointestinal tract
FR2945947B1 (fr) 2009-05-29 2011-07-29 Flamel Tech Sa Compositions pharmaceutiques flottantes a liberation controlee
US20120100212A1 (en) 2009-07-06 2012-04-26 Kyorin Pharmaceutical, Co., Ltd. Tablet having hollow structure
EP2361615A1 (en) 2010-02-19 2011-08-31 Alfred E. Tiefenbacher GmbH & Co. KG Dipyridamole prolonged-release tablet
EP2544666A2 (en) 2010-03-09 2013-01-16 Council of Scientific and Industrial Research Gastroretentive, extended release composition of therapeutic agent
KR101767288B1 (ko) * 2010-03-31 2017-08-10 모찌다 세이야쿠 가부시끼가이샤 복용 용이성 고형 제제
CN101919817B (zh) * 2010-07-23 2012-05-30 山东齐都药业有限公司 一种拉呋替丁胃内滞留控制释放组合物
CA2847614C (en) 2011-09-30 2018-10-23 Mochida Pharmaceutical Co., Ltd. Easily dosable solid preparation
DE102012102414A1 (de) 2012-03-21 2013-10-10 Michael Dittgen Pharmazeutische Zusammensetzung für die einmal tägliche Anwendung antidiabetischer Arzneimittel wie Metformin mit Zwei-Puls-Freisetzung
WO2013168179A2 (en) * 2012-04-03 2013-11-14 Rubicon Research Private Limited Controlled release pharmaceutical formulations of antiviral agents
CN103110601B (zh) * 2013-02-04 2014-10-29 成都恒瑞制药有限公司 一种格列齐特胃漂浮片及其制备方法
FR3014692B1 (fr) * 2013-12-18 2016-01-29 Ethypharm Sa Compositions pharmaceutiques orales a retention gastrique.
TWI732337B (zh) * 2014-06-20 2021-07-01 美商梅琳塔有限責任公司 醫藥組成物及其用途
EP3429573A4 (en) 2016-03-17 2019-10-30 Thiogenesis Therapeutics, Inc. COMPOSITIONS FOR THE CONTROLLED RELEASE OF CYSTEAMINE AND FOR SYSTEMIC TREATMENT OF CYSTEAMIN SENSITIVE DISEASES
CN107184560B (zh) * 2017-06-03 2021-02-02 寿光富康制药有限公司 二甲双胍胃滞留片及制备方法
JP7208982B2 (ja) 2017-09-20 2023-01-19 チオジェネシス セラピューティクス, インコーポレイテッド システアミン感受性障害の治療方法
US11666546B2 (en) 2017-12-18 2023-06-06 Tris Pharma, Inc GHB pharmaceutical compositions comprising a floating interpenetrating polymer network forming system
WO2019126218A1 (en) * 2017-12-18 2019-06-27 Tris Pharma, Inc. Modified release drug powder composition comprising gastro-retentive raft forming systems having trigger pulse drug release
CN109602714B (zh) * 2018-12-29 2020-06-12 广东中润药物研发有限公司 一种利伐沙班胃滞留片及其制备方法
GB2599950A (en) * 2020-10-16 2022-04-20 Zentiva Ks Pharmaceutical compositions with low amounts of nitrosamine impurities and methods for producing the same
KR20230131480A (ko) * 2021-01-13 2023-09-13 듀폰 뉴트리션 유에스에이 인코포레이티드 위체류 약물 전달 시스템

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS61148115A (ja) * 1984-12-21 1986-07-05 Tooa Eiyoo Kk 難溶性薬物の徐放性製剤及びその製造法
GB8618847D0 (en) * 1986-08-01 1986-09-10 Smith Kline French Lab Pharmaceutical formulations
FR2653337B1 (fr) * 1989-10-23 1992-02-07 Dow Corning Sa Element a liberation prolongee et procede pour le fabriquer.
US6635280B2 (en) 1997-06-06 2003-10-21 Depomed, Inc. Extending the duration of drug release within the stomach during the fed mode
PT1003476E (pt) * 1997-08-11 2005-05-31 Alza Corp Forma de dosagem de agente activo de libertacao prolongada adaptada para retencao gastrica
IN186245B (xx) 1997-09-19 2001-07-14 Ranbaxy Lab Ltd
AU736951C (en) 1998-03-19 2003-02-20 Bristol-Myers Squibb Company Biphasic controlled release delivery system for high solubility pharmaceuticals and method
EE200100153A (et) * 1998-09-14 2002-06-17 Ranbaxy Laboratories Limited Kontrollitav ravimiväljutussüsteem ravimite suukaudseks manustamiseks, mis pakub ajalist ja ruumilist kontrolli
US6797283B1 (en) 1998-12-23 2004-09-28 Alza Corporation Gastric retention dosage form having multiple layers
US6635281B2 (en) * 1998-12-23 2003-10-21 Alza Corporation Gastric retaining oral liquid dosage form
IL143846A0 (en) * 1998-12-23 2002-04-21 Alza Corp Dosage forms comprising porous particles
IL151553A0 (en) * 2000-03-03 2003-04-10 Ranbaxy Lab Ltd Orally administered controlled delivery system for once daily administration of ciprofloxacin
WO2003097018A1 (en) * 2002-02-04 2003-11-27 Ranbaxy Laboratories Limited Hydrodynamically balancing oral drug delivery system with biphasic release
EP1411901B1 (en) * 2001-07-04 2010-08-18 Sun Pharma Advanced Research Company Ltd Gastric retention controlled drug delivery system
GB0205253D0 (en) * 2002-03-06 2002-04-17 Univ Gent Immediate release pharmaceutical granule compositions and a continuous process for making them
WO2003101431A1 (en) 2002-06-04 2003-12-11 J.B. Chemicals & Pharmaceuticals Ltd. Pharmaceutical composition for controlled drug delivery system
WO2005060942A1 (en) * 2003-12-19 2005-07-07 Aurobindo Pharma Ltd Extended release pharmaceutical composition of metformin

Also Published As

Publication number Publication date
BRPI0612901B8 (pt) 2021-05-25
US9629800B2 (en) 2017-04-25
JP5199084B2 (ja) 2013-05-15
WO2007010400A2 (en) 2007-01-25
BRPI0612901A2 (pt) 2010-12-07
JP2009501777A (ja) 2009-01-22
CN101237858B (zh) 2012-07-04
KR101367814B1 (ko) 2014-02-27
CA2616081C (en) 2013-09-10
WO2007010400A3 (en) 2007-04-05
BRPI0612901B1 (pt) 2020-08-04
CN101237858A (zh) 2008-08-06
ATE396710T1 (de) 2008-06-15
EP1745775B1 (en) 2008-05-28
CA2616081A1 (en) 2007-01-25
DE602005007205D1 (de) 2008-07-10
AU2006271314B2 (en) 2011-07-07
RU2008106220A (ru) 2009-08-27
RU2376983C2 (ru) 2009-12-27
US20080220060A1 (en) 2008-09-11
EP1904034A2 (en) 2008-04-02
EP1745775A1 (en) 2007-01-24
KR20080048461A (ko) 2008-06-02
AU2006271314A1 (en) 2007-01-25

Similar Documents

Publication Publication Date Title
HK1122729A1 (en) Gastroretentive formulations and manufacturing process thereof
LUC00153I2 (xx)
RS50812B (sr) Suva granulisana kompozicija koja sadrži emtricitabin i tenofovir df
ATE473713T1 (de) Gehörschutzstöpsel
MX2012006543A (es) Composicion acuosa antitranspirante/desodorante.
IL184051A (en) Acetylated GLP-1 compounds, containing and using pharmaceutical preparations
MX2007015424A (es) Formulaciones ungueales topicas.
ATE501520T1 (de) Kaltfeldemitter
DK1896006T3 (da) Fremstillingmetode for entacapon-holdige granuler til orale doseringsformet
DK1861073T4 (da) Fremgangsmåde til fremstilling af calciumsammensætninger i en kontinuerlig fluid bed
EA200800927A1 (ru) КОМПОЗИЦИЯ ДЛЯ АЭРОЗОЛЬНОЙ ИНГАЛЯЦИИ β-АГОНИСТОВ
UA92894C2 (ru) Способ приготовления и применения композиции адсорбента фосфата, адсорбент фосфата, композиция адсорбента фосфата
PT1810676E (pt) Formulações de levetiracetam e métodos para a sua preparação
WO2006091836A8 (en) Formulations of ladostigil tartrate
WO2006060542A3 (en) Formulations of substituted benzoxazoles
TW200517117A (en) Stabilized compositions containing an oxygen-labile active agent
TW200640932A (en) Clopidogrel base suitable for pharmaceutical formulation and preparation thereof
DE602008005403D1 (de) Tierstreu und herstellungsverfahren dafür
PL2046813T3 (pl) Pochodne metotreksatu wiążące proteiny oraz leki zawierające te pochodne
RS20050933A (xx) Postupak za dobijanje nepeptidnih derivata supstituisanog spirobenzoazepina
WO2007066200A3 (en) Inhibitors of cysteine proteases, the pharmaceutical compositions thereof and their therapeutic applications
WO2007002881A3 (en) Compositions and methods of use of derivatized flavanols
WO2006079922A3 (en) Fast-disintegrating microporous binder and process for making it
TW200621224A (en) Pharmaceutical composition
PL378106A1 (pl) Sposób wytwarzania zawierającej fibrat kompozycji farmaceutycznej w postaci tabletek oraz tabletki otrzymane tym sposobem